Clinical Trial Update: Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating savolitinib for MET-amplified metastatic or unresectable colorectal cancer was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Adenocarcinoma
• Colon Cancer
• Colorectal Carcinoma
• Rectal Adenocarcinoma
• Rectal Cancer
• Stage Iiia Colon Cancer
• Stage Iiia Rectal Cancer
• Stage Iiib Colon Cancer
• Stage Iiib Rectal Cancer
• Stage Iiic Colon Cancer
• Stage Iiic Rectal Cancer
• Stage Iva Colon Cancer
• Stage Iva Rectal Cancer
• Stage Ivb Colon Cancer
• Stage Ivb Rectal Cancer
• Stage Ivc Colon Cancer
• Stage Ivc Rectal Cancer
• Unresectable Colon Adenocarcinoma
• Unresectable Rectal Adenocarcinoma

Drugs mentioned

• Savolitinib (savolitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2023-08-08